Published in Clin Cancer Res on May 01, 2002
Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proc Natl Acad Sci U S A (2006) 6.33
Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat (2007) 3.78
PTEN function: how normal cells control it and tumour cells lose it. Biochem J (2004) 3.06
mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro Oncol (2010) 1.65
mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol (2005) 1.56
Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neuro Oncol (2007) 1.53
Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patients. Br J Cancer (2006) 1.47
Update on molecular findings, management and outcome in low-grade gliomas. Nat Rev Neurol (2010) 1.43
The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. Curr Genomics (2007) 1.33
Targeted therapy for malignant glioma patients: lessons learned and the road ahead. Neurotherapeutics (2009) 1.22
A microfluidic platform for systems pathology: multiparameter single-cell signaling measurements of clinical brain tumor specimens. Cancer Res (2010) 1.20
Nonredundant functions for Akt isoforms in astrocyte growth and gliomagenesis in an orthotopic transplantation model. Cancer Res (2011) 1.17
Activated Akt as an indicator of prognosis in gastric cancer. Virchows Arch (2008) 1.16
FoxM1B regulates NEDD4-1 expression, leading to cellular transformation and full malignant phenotype in immortalized human astrocytes. Cancer Res (2010) 1.14
PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome. Neuro Oncol (2012) 1.03
PI3Kinase signaling in glioblastoma. J Neurooncol (2010) 1.01
Emerging treatment strategies for glioblastoma multiforme. EMBO Mol Med (2014) 1.00
The combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas. Front Oncol (2013) 0.98
ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines. J Pharmacol Exp Ther (2012) 0.97
Loss of PTEN is not associated with poor survival in newly diagnosed glioblastoma patients of the temozolomide era. PLoS One (2012) 0.97
PTEN as a prognostic and predictive marker in postoperative radiotherapy for squamous cell cancer of the head and neck. PLoS One (2012) 0.94
MARCKS regulates growth and radiation sensitivity and is a novel prognostic factor for glioma. Clin Cancer Res (2012) 0.93
Phase II study of PX-866 in recurrent glioblastoma. Neuro Oncol (2015) 0.92
Inhibition of HSP27 alone or in combination with pAKT inhibition as therapeutic approaches to target SPARC-induced glioma cell survival. Mol Cancer (2012) 0.88
Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma. PLoS One (2014) 0.85
Combined PTEN Mutation and Protein Expression Associate with Overall and Disease-Free Survival of Glioblastoma Patients. Transl Oncol (2014) 0.85
Signal transduction molecules in gliomas of all grades. J Neurooncol (2008) 0.85
PI3K inhibition synergizes with glucocorticoids but antagonizes with methotrexate in T-cell acute lymphoblastic leukemia. Oncotarget (2015) 0.84
Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model. PLoS One (2013) 0.84
MicroRNA-1908 functions as a glioblastoma oncogene by suppressing PTEN tumor suppressor pathway. Mol Cancer (2015) 0.82
The impact of age on oncogenic potential: tumor-initiating cells and the brain microenvironment. Aging Cell (2013) 0.82
Dissecting DNA repair in adult high grade gliomas for patient stratification in the post-genomic era. Oncotarget (2014) 0.81
Radiation-induced upregulation of telomerase activity escapes PI3-kinase inhibition in two malignant glioma cell lines. Int J Oncol (2013) 0.81
PTEN suppresses SPARC-induced pMAPKAPK2 and inhibits SPARC-induced Ser78 HSP27 phosphorylation in glioma. Neuro Oncol (2013) 0.81
Emerging therapies in pancreas cancer. J Gastrointest Oncol (2011) 0.80
The prognostic value of phosphorylated AKT expression in non-small cell lung cancer: a meta-analysis. PLoS One (2013) 0.79
The role of AKT isoforms in glioblastoma: AKT3 delays tumor progression. J Neurooncol (2016) 0.77
Focused ultrasound-aided immunomodulation in glioblastoma multiforme: a therapeutic concept. J Ther Ultrasound (2016) 0.77
Cerebral Gluconeogenesis and Diseases. Front Pharmacol (2017) 0.75
Characterization of PTEN mutations in brain cancer reveals that pten mono-ubiquitination promotes protein stability and nuclear localization. Oncogene (2017) 0.75
Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas. Cancer (2017) 0.75
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature (2010) 15.63
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 15.42
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol (2010) 14.79
Diverse somatic mutation patterns and pathway alterations in human cancers. Nature (2010) 10.83
A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell (2006) 10.06
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med (2006) 7.10
Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A (2005) 6.54
An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg (2011) 6.32
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell (2006) 6.15
Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration. Nature (2004) 5.85
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Neural stem cells and the origin of gliomas. N Engl J Med (2005) 5.43
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst (2005) 4.63
Corridors of migrating neurons in the human brain and their decline during infancy. Nature (2011) 4.12
Glioma extent of resection and its impact on patient outcome. Neurosurgery (2008) 4.02
Functional outcome after language mapping for glioma resection. N Engl J Med (2008) 4.01
Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol (2002) 3.99
High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res (2005) 3.98
Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg (2003) 3.91
Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc Natl Acad Sci U S A (2012) 3.21
Patterns of care for adults with newly diagnosed malignant glioma. JAMA (2005) 3.08
Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol (2008) 2.92
High gamma activity in response to deviant auditory stimuli recorded directly from human cortex. J Neurophysiol (2005) 2.88
Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood (2003) 2.76
Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol (2008) 2.71
Categorical speech representation in human superior temporal gyrus. Nat Neurosci (2010) 2.67
Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol (2003) 2.63
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov (2012) 2.61
Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. Neuro Oncol (2007) 2.56
Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res (2010) 2.56
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol (2006) 2.49
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res (2006) 2.44
Contribution of Notch signaling activation to human glioblastoma multiforme. J Neurosurg (2007) 2.43
Functional mapping-guided resection of low-grade gliomas in eloquent areas of the brain: improvement of long-term survival. Clinical article. J Neurosurg (2010) 2.42
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs (2005) 2.30
Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol (2013) 2.25
Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity. J Neurosurg (2003) 2.24
Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts. Neuro Oncol (2009) 2.23
Comanagement of surgical patients between neurosurgeons and hospitalists. Arch Intern Med (2010) 2.22
PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. Cancer Res (2008) 2.20
Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas. J Neurosurg (2010) 2.19
Modern surgical outcomes following surgery for sphenoid wing meningiomas. J Neurosurg (2013) 2.16
Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology (2009) 2.15
Natural history and surgical management of incidentally discovered low-grade gliomas. J Neurosurg (2011) 2.14
Reoperation for recurrent high-grade glioma: a current perspective of the literature. Neurosurgery (2014) 2.11
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol (2006) 2.11
Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res (2004) 2.10
Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J Neurosurg (2005) 2.07
The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma. Neurosurgery (2015) 2.06
Symptomatic enlarged cervical anterior epidural venous plexus in a patient with Marfan syndrome. AJNR Am J Neuroradiol (2002) 2.05
Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol Cancer Res (2009) 2.05
New insights into PTEN. J Cell Sci (2007) 2.04
Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol (2007) 2.01
Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res (2002) 1.96
A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem J (2008) 1.96
Non-stem cell origin for oligodendroglioma. Cancer Cell (2010) 1.95
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol (2011) 1.92
Five-dimensional neuroimaging: localization of the time-frequency dynamics of cortical activity. Neuroimage (2008) 1.88
A role for PI 3-kinase and PKB activity in the G2/M phase of the cell cycle. Curr Biol (2002) 1.88
Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. Cancer Res (2010) 1.81
Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg (2008) 1.79
Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain. Exp Neurol (2005) 1.78
Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy. J Neurosurg (2007) 1.77
VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: results of a prospective clinical trial. J Clin Oncol (2002) 1.76
Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imaging. Brain Res Brain Res Protoc (2005) 1.74
Low-grade gliomas in adults. J Neurosurg (2011) 1.73
A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation. Nat Genet (2012) 1.73
Surgical technique of temporary arterial occlusion in the operative management of spinal hemangioblastomas. World Neurosurg (2010) 1.72
Asymmetry-defective oligodendrocyte progenitors are glioma precursors. Cancer Cell (2011) 1.67
Gamma Knife radiosurgery for brain metastases from primary breast cancer. Int J Radiat Oncol Biol Phys (2009) 1.67
The relevance of Simpson Grade I and II resection in modern neurosurgical treatment of World Health Organization Grade I meningiomas. J Neurosurg (2010) 1.67
Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism. Mol Biol Cell (2004) 1.67
Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. J Neurosurg (2008) 1.66
EGFR signals to mTOR through PKC and independently of Akt in glioma. Sci Signal (2009) 1.66
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol (2009) 1.66
Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. J Neurosurg (2012) 1.64
Prognostic significance of intracranial dissemination of glioblastoma multiforme in adults. J Neurosurg (2005) 1.63
Magnetoencephalographic imaging of resting-state functional connectivity predicts postsurgical neurological outcome in brain gliomas. Neurosurgery (2012) 1.61
Imaging features of invasion and preoperative and postoperative tumor burden in previously untreated glioblastoma: Correlation with survival. Surg Neurol Int (2010) 1.61
Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery. J Neurooncol (2004) 1.61
A design of phase II cancer trials using total and complete response endpoints. Stat Med (2005) 1.60
Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol (2008) 1.59
Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res (2002) 1.59
Mapping functional connectivity in patients with brain lesions. Ann Neurol (2008) 1.58